Advanced Life Sciences Offers Testimony at Senate Hearing on Defending Against Public Health Threats
CHICAGO, Oct. 4 /PRNewswire/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the company provided testimony at the U.S. Senate Committee on Appropriations Subcommittee on Labor, Health and Human Services (HHS) Hearing on "Defending Against Public Health Threats" on September 29, 2010 in Washington, D.C.
Advanced Life Sciences chairman and chief executive officer, Michael T. Flavin, Ph.D., commented on the critical need to invest in the development of late-stage medical countermeasures that can defend against public health threats, such as emerging infectious diseases as well as bioterrorism. He commended the efforts of HHS to support development of medical countermeasures to combat public health threats, and urged the department to balance its portfolio by including late-stage products nearing FDA approval which can be efficiently and cost effectively studied and which, if approved, could rapidly be made available to protect the public.
"Advanced Life Sciences has responded to the critical threat of bioterrorism by developing its novel antibiotic, Restanza™, to protect against infection from inhaled anthrax, plague and tularemia," said Dr. Flavin. "Consistent with the priorities articulated by HHS, our company is committed to advancing Restanza through the final stage of clinical testing with the goal of gaining FDA approval and providing a safe and effective n